Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Sep;95(1):55–66. doi: 10.1111/j.1476-5381.1988.tb16548.x

Contribution of beta 1- and beta 2-adrenoceptors of human atrium and ventricle to the effects of noradrenaline and adrenaline as assessed with (-)-atenolol.

H Lemoine 1, H Schönell 1, A J Kaumann 1
PMCID: PMC1854142  PMID: 2851354

Abstract

1. (-)-Atenolol was used as a tool to assess the function of beta 1- and beta 2-adrenoceptors in human heart. Right atrial and left ventricular preparations from patients undergoing open heart surgery were set up to contract isometrically. Membrane particles were prepared for beta-adrenoceptor labelling with [3H]-(-)-bupranolol and adenylate cyclase assays. 2. The positive inotropic effects of (-)-noradrenaline were antagonized to a similar extent by (-)-atenolol in atrial and ventricular preparations. (-)-Atenolol consistently antagonized the effects of (-)-adrenaline to a lesser extent than those of (-)-noradrenaline in atrial preparations. In ventricular preparations (-)-atenolol antagonized the effects of low concentrations of (-)-adrenaline to a lesser extent than those of high concentrations. 3. pKB values (M) of (-)-atenolol, estimated with non-linear analysis from the blockade of the positive inotropic effects of the catecholamines, were 7.4 for beta 1-adrenoceptors and 6.0 for beta 2-adrenoceptors. 4. (-)-Atenolol inhibited the binding of [3H]-(-)-bupranolol to ventricular beta 1-adrenoceptors with a pKD (M) of 5.9 and to ventricular beta 2-adrenoceptors with a pKD of 4.6. 5. (-)-Atenolol inhibited the catecholamine-induced adenylate cyclase stimulation in the atrium and ventricle with pKB values of 5.8-6.4 for beta 1- and pKB values of 4.7-5.7 for beta 2-adrenoceptors. The binding and cyclase assays suggest a partial affinity loss for (-)-atenolol inherent to membrane preparations. 6. beta 1-Adrenoceptors mediate the maximum positive inotropic effects of (-)-noradrenaline in both the atrium and ventricle of man. beta 2-Adrenoceptors appear to be capable of mediating maximal positive inotropic effects of (-)-adrenaline in atrium. In contrast, ventricular beta 2-adrenoceptors mediated only submaximal effects of (-)-adrenaline.

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blinks J. R. Convenient apparatus for recording contractions of isolated heart muscle. J Appl Physiol. 1965 Jul;20(4):755–757. doi: 10.1152/jappl.1965.20.4.755. [DOI] [PubMed] [Google Scholar]
  2. Bristow M. R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., Zera P., Menlove R., Shah P., Jamieson S. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep;59(3):297–309. doi: 10.1161/01.res.59.3.297. [DOI] [PubMed] [Google Scholar]
  3. Brodde O. E., Karad K., Zerkowski H. R., Rohm N., Reidemeister J. C. Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding. Circ Res. 1983 Dec;53(6):752–758. doi: 10.1161/01.res.53.6.752. [DOI] [PubMed] [Google Scholar]
  4. Conway F. J., Fitzgerald J. D., McAinsh J., Rowlands D. J., Simpson W. T. Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol. 1976 Apr;3(2):267–272. doi: 10.1111/j.1365-2125.1976.tb00602.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ehle B., Lemoine H., Kaumann A. J. Improved evaluation of binding of ligands to membranes containing several receptor-subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1985 Oct;331(1):52–59. doi: 10.1007/BF00498851. [DOI] [PubMed] [Google Scholar]
  6. Gille E., Lemoine H., Ehle B., Kaumann A. J. The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol. 1985 Oct;331(1):60–70. doi: 10.1007/BF00498852. [DOI] [PubMed] [Google Scholar]
  7. Hedberg A., Kempf F., Jr, Josephson M. E., Molinoff P. B. Coexistence of beta-1 and beta-2 adrenergic receptors in the human heart: effects of treatment with receptor antagonists or calcium entry blockers. J Pharmacol Exp Ther. 1985 Sep;234(3):561–568. [PubMed] [Google Scholar]
  8. Heitz A., Schwartz J., Velly J. Beta-adrenoceptors of the human myocardium: determination of beta 1 and beta 2 subtypes by radioligand binding. Br J Pharmacol. 1983 Dec;80(4):711–717. doi: 10.1111/j.1476-5381.1983.tb10062.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kaumann A. J., Birnbaumer L. Studies on receptor-mediated activation of adenylyl cyclases. IV. Characteristics of the adrenergic receptor coupled to myocardial adenylyl cyclase: stereospecificity for ligands and determination of apparent affinity constants for beta-blockers. J Biol Chem. 1974 Dec 25;249(24):7874–7885. [PubMed] [Google Scholar]
  10. Kaumann A. J., Blinks J. R. Stimulant and depressant effects of beta-adrenoceptor blocking agents on isolated heart muscle. A positive inotropic effect not mediated through andrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1980 Apr;311(3):205–218. doi: 10.1007/BF00569401. [DOI] [PubMed] [Google Scholar]
  11. Kaumann A. J., Lemoine H. Beta 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn Schmiedebergs Arch Pharmacol. 1987 Apr;335(4):403–411. doi: 10.1007/BF00165555. [DOI] [PubMed] [Google Scholar]
  12. Kaumann A. J., Lemoine H. Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency. Naunyn Schmiedebergs Arch Pharmacol. 1985 Oct;331(1):27–39. doi: 10.1007/BF00498849. [DOI] [PubMed] [Google Scholar]
  13. Kaumann A. J., Lobnig B. M. Mode of action of (-)-pindolol on feline and human myocardium. Br J Pharmacol. 1986 Sep;89(1):207–218. doi: 10.1111/j.1476-5381.1986.tb11137.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kaumann A. J., Marano M. On equilibrium dissociation constants for complexes of drug-receptor subtypes. Selective and non-selective interactions of partial agonists with two plausible beta-adrenoceptor subtypes mediating positive chronotropic effects of (-)-isoprenaline in kitten atria. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):192–201. doi: 10.1007/BF00500480. [DOI] [PubMed] [Google Scholar]
  15. Kaumann A. J., Morris T. H., Bojar H. Heart beta-receptors: on the functional role of heterogeneous binding sites. J Recept Res. 1983;3(1-2):61–70. doi: 10.3109/10799898309041923. [DOI] [PubMed] [Google Scholar]
  16. Kaumann A. J. On spare beta-adrenoceptors of inotropic effect of catecholamines in kitten ventricle. Naunyn Schmiedebergs Arch Pharmacol. 1978 Nov;305(2):97–102. doi: 10.1007/BF00508277. [DOI] [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Lemoine H., Ehle B., Kaumann A. J. Direct labelling of beta 2-adrenoceptors. Comparison of binding potency of 3H-ICI 118,551 and blocking potency of ICI 118,551. Naunyn Schmiedebergs Arch Pharmacol. 1985 Oct;331(1):40–51. doi: 10.1007/BF00498850. [DOI] [PubMed] [Google Scholar]
  19. Lemoine H., Kaumann A. J. A model for the interaction of competitive antagonists with two receptor-subtypes characterized by a Schild-plot with apparent slope unity. Agonist-dependent enantiomeric affinity ratios for bupranolol in tracheae but not in right atria of guinea pigs. Naunyn Schmiedebergs Arch Pharmacol. 1983 Mar;322(2):111–120. doi: 10.1007/BF00512383. [DOI] [PubMed] [Google Scholar]
  20. Lemoine H., Kaumann A. J. A novel analysis of concentration-dependence of partial agonism Ring-demethylation of bupranolol results in a high affinity partial agonist (K 105) for myocardial and tracheal beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1982 Aug;320(2):130–144. doi: 10.1007/BF00506313. [DOI] [PubMed] [Google Scholar]
  21. McAinsh J. Clinical pharmacokinetics of atenolol. Postgrad Med J. 1977;53 (Suppl 3):74–78. [PubMed] [Google Scholar]
  22. Morris T. H., Kaumann A. J. Different steric characteristics of beta 1- and beta 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1984 Sep;327(2):176–179. doi: 10.1007/BF00500913. [DOI] [PubMed] [Google Scholar]
  23. Morris T. H., Sandrock K., Kaumann A. J. 3H-(-)-Bupranolol, a new beta-adrenoceptor radioligand: characterization of its binding to kitten heart beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):19–25. doi: 10.1007/BF00506251. [DOI] [PubMed] [Google Scholar]
  24. Mügge A., Posselt D., Reimer U., Schmitz W., Scholz H. Effects of the beta 2-adrenoceptor agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium. Klin Wochenschr. 1985 Jan 2;63(1):26–31. [PubMed] [Google Scholar]
  25. Rehling M., Svendsen T. L., Maltbaek N., Tangø M., Trap-Jensen J. Haemodynamic effects of atenolol, pindolol and propranolol during adrenaline infusion in man. Eur J Clin Pharmacol. 1986;30(6):659–663. doi: 10.1007/BF00608212. [DOI] [PubMed] [Google Scholar]
  26. Robberecht P., Delhaye M., Taton G., De Neef P., Waelbroeck M., De Smet J. M., Leclerc J. L., Chatelain P., Christophe J. The human heart beta-adrenergic receptors. I. Heterogeneity of the binding sites: presence of 50% beta 1- and 50% beta 2-adrenergic receptors. Mol Pharmacol. 1983 Sep;24(2):169–173. [PubMed] [Google Scholar]
  27. STEPHENSON R. P. A modification of receptor theory. Br J Pharmacol Chemother. 1956 Dec;11(4):379–393. doi: 10.1111/j.1476-5381.1956.tb00006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974 Apr;58(2):541–548. doi: 10.1016/0003-2697(74)90222-x. [DOI] [PubMed] [Google Scholar]
  29. Stiles G. L., Taylor S., Lefkowitz R. J. Human cardiac beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci. 1983 Aug 1;33(5):467–473. doi: 10.1016/0024-3205(83)90796-8. [DOI] [PubMed] [Google Scholar]
  30. Waelbroeck M., Taton G., Delhaye M., Chatelain P., Camus J. C., Pochet R., Leclerc J. L., De Smet J. M., Robberecht P., Christophe J. The human heart beta-adrenergic receptors. II. Coupling of beta 2-adrenergic receptors with the adenylate cyclase system. Mol Pharmacol. 1983 Sep;24(2):174–182. [PubMed] [Google Scholar]
  31. Zerkowski H. R., Ikezono K., Rohm N., Reidemeister J. C., Brodde O. E. Human myocardial beta-adrenoceptors: demonstration of both beta 1- and beta 2-adrenoceptors mediating contractile responses to beta-agonists on the isolated right atrium. Naunyn Schmiedebergs Arch Pharmacol. 1986 Feb;332(2):142–147. doi: 10.1007/BF00511404. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES